Delenex Therapeutics makes two senior appointments
Eric de La Fortelle joins as ceo and Jakob Schlapbach as cfo
La Fortelle was previously global head of external research and technologies at F. Hoffmann-La Roche and more recently global head, emerging technologies. His scientific work contributed to the field of protein structure determination and he was the initial lead author of the SHARP software, which contributed to the resolution of more than 1,000 protein structures by X-ray crystallography.
Schlapbach joined Delenex last December 2010 as cfo. He brings more than 30 years of banking and industrial financing experience to the company. He was cfo of Cytos Biotechnology for more than 10 years until mid-2010 and held the same position at Ascom group between 1994 and 2000.
Thomas Hecht, chairman of Delenex, said: ‘We are pleased and proud to have attracted two managers of such a high calibre to Delenex.’
Delenex Therapeutics AG is developing therapeutic PENTRA antibody fragments targeting serious medical diseases with high unmet need.
Delenex is a spin-off from ESBATech before its acquisition by Alcon in September 2009 and operates out of laboratories and offices in Zürich-Schlieren.
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
The path to commercial allogeneic iPSC therapies
The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Research & Development
The IND advantage: why early derisking is a strategic imperative for complex biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Research & Development
Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies
Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
Research & Development
Lonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation
New GS Ori‑Go vector technology supports titers higher than 11 g/L and reliable bulk pool stability, enabling more predictable material generation and shortened cell line development timelines